KRAS mutations play a key role in the pathogenesis of acute myeloid leukemia (AML), occurring in 10–15% of cases and being associated with aggressive disease progression and therapeutic resistance. Despite significant advances in the treatment of KRAS-mutant solid tumors, including the approval of allele-specific G12C inhibitors, the potential of pan-KRAS inhibitors in hematologic malignancies remains insufficiently explored. This study evaluates a pan-KRAS inhibitor structurally analogous to BI-2493 in the SKM-1 cell line model (KRAS G12D+). In vitro results demonstrate reduced cell viability, induction of apoptosis (Annexin V+), and suppression of the KRAS–MEK–ERK signaling cascade. The findings are contextualized with data from Popow et al. and Revvity/Boehringer Ingelheim, enabling a comparative analysis of G12D-mutant model sensitivity across tumor types. The discussion addresses the potential for in vivo xenograft testing, combination strategies with SHP2 and BCL2 inhibitors, and the application of PROTAC degraders as alternative approaches in resistant settings. These results provide the first evidence of pan-KRAS inhibitor efficacy in an AML model, highlighting its relevance for targeted therapy in hematologic malignancies and supporting further preclinical investigation aimed at integration into personalized oncology protocols.

KRAS, acute myeloid leukemia, AML, pan-KRAS inhibitors, G12D, targeted therapy, BI-2493, apoptosis, MAPK signaling, protein degradation, SHP2, resistance

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. – 2023. – Nature – Source: [Electronic resource] – URL: https://www.nature.com/articles/s41586-023-06123-3 (accessed 10.05.2025).

Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification. – 2025. – Molecular Cancer Therapeutics. – Source: [Electronic resource] – URL: https://aacrjournals.org/mct/article/24/4/550/754287/Pan-KRAS-Inhibitors-BI-2493-and-BI-2865-Display (accessed 11.05.2025).

Breaking down KRAS: small-molecule degraders for cancer therapy. – 2025. – Signal Transduction and Targeted Therapy – Source: [Electronic resource] – URL: https://www.nature.com/articles/s41392-025-02172-4 (accessed 13.05.2025).

Johannes Popow et al. ,Targeting cancer with small-molecule pan-KRAS degraders.Science385,1338-1347(2024). DOI:10.1126/science.adm8684 – Source: [Electronic resource] – URL: https://www.science.org/doi/10.1126/science.adm8684 (accessed 14.05.2025).

Jacobio Pharma Completes First Patient Dosage of Pan-KRAS Inhibitor. – 2024. – Jacobio – Source: [Electronic resource] – URL: https://www.jacobiopharma.com/en/news/pan-kras-fpi (accessed 15.05.2025).

What’s new in KRAS mutation research? – 2025. – MD Anderson Center – Source: [Electronic resource] – URL: https://www.mdanderson.org/cancerwise/what-s-new-in-kras-mutation-research-.h00-159696756.html (accessed 15.05.2025).

Park J, Park H, Byun JM, Hong J, Shin DY, Koh Y, Yoon SS. Pan-RAF inhibitor LY3009120 is highly synergistic with low-dose cytarabine, but not azacitidine, in acute myeloid leukemia with RAS mutations. Oncol Lett. 2021 Nov;22(5):745. doi: 10.3892/ol.2021.13006. Epub 2021 Aug 20. PMID: 34539849; PMCID: PMC8436357.

Wu X, Song W, Cheng C, Liu Z, Li X, Cui Y, Gao Y and Li D (2023) Small molecular inhibitors for KRAS-mutant cancers. Front. Immunol. 14:1223433. doi: 10.3389/fimmu.2023.1223433.

The impact of pan-KRAS inhibitors on cancer drug discovery. – 2025. – Revvity – Source: [Electronic resource] – URL: https://resources.revvity.com/pdfs/pbr-impact-of-pan-kras-inhibitors-on-cancer-drug-discovery.pdf (accessed 18.05.2025).